linjc16/ctgov huggingface dataset:
Embolization of Pelvic Veins in Treatment of Pelvic Congestion Syndrome

Study Overview
=================
Brief Summary
-----------------
Chronic pelvic pain is defined as chronic or persistent pain perceived in structures related to the pelvis of either men or women for more than 6 months according to The International Association for the Study of Pain. In other words, chronic pelvic pain with associated ovarian vein varicosities is termed pelvic congestion syndrome and is an important but under-diagnosed condition

Official Title
-----------------
Effectiveness of Embolization of Pelvic Veins in Treatment of Pelvic Congestion Syndrome

Conditions
-----------------
Pelvic Congestive Syndrome

Intervention / Treatment
-----------------
* Device: coil
* Device: hystoacryl glue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical symptoms of pelvic congestion syndrome documented by Doppler ultrasound Failed medical treatment. Exclusion Criteria: Endometriosis. Uterine fibroids. Previous pelvic operations. Urological diseases.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: coil group<br>micro coils | Device: coil<br>* microcoils<br>|
| Experimental: glue group<br>hystoacryl mixed with lipidol | Device: hystoacryl glue<br>* hystoacryl mixed with lipidol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of treated patients with different interventions |  | 6 months |
Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos

Study Overview
=================
Brief Summary
-----------------
This database has for objective to include the medical data of patients which underwent a vaginal Cesarean Section in our establishment. This collection will allow to determine the risk factors of the maternal morbi-mortality and to estimate the long-term results

Detailed Description
-----------------
It is about an operating technique little known which is used as an alternative of the abdominal Cesarean Section for very premature pregnancies and the main indication is the maternal rescue. It has several advantages: simplicity of the technique, the dissection of tissues is limited, low risk of bleeding and no abdominal scar. The purpose is to determine the risk factors of the maternal morbi-mortality and to estimate the long-term results

Official Title
-----------------
Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos

Conditions
-----------------
Complications; Cesarean Section

Intervention / Treatment
-----------------
* Procedure: vaginal Cesarean Section


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients operated to vaginal Cesarean in Hospital Rene DUBOS Exclusion Criteria: patients followed in a maternity which do not participate to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| vaginal Cesarean Section<br>patients operated to vaginal Cesarean Section | Procedure: vaginal Cesarean Section<br>* follow-up to patients operated for vaginal Cesarean Section<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors of the maternal morbi-mortality by collection of adverse events during the pregnancy, concomitant pathologies and antecedents |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Complications; Cesarean Section
Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening?

Study Overview
=================
Brief Summary
-----------------
To establish whether provision of numerical data, framed as event rates and illustrated by pictograms, and including figures for all-cause mortality, affects subjects' attitudes to colorectal cancer (CRC) screening. Design and Intervention. Randomised questionnaire and telephone study comparing the responses of a control group given the standard National Health Service (NHS) CRC screening information with the responses of an intervention group given the same information but enhanced with additional numerical and pictorial information. Setting

Official Title
-----------------
THE RESULTS OF A RANDOMISED CONTROLLED QUESTIONNAIRE-BASED TRIAL ON WHETHER PROVISION OF NUMERICAL AND PICTORIAL INFORMATION ON RISK AND BENEFIT AFFECTS THE UPTAKE OF COLORECTAL CANCER SCREENING?

Conditions
-----------------
Colorectal Cancer Screening

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 60 - 70 - Exclusion Criteria: No previous cancer or previous colonoscopy Not able to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control<br>given standard nhs advice leaflet | |
| interventional<br>given standard nhs advice leaflet with numerical information and pictograms | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the two groups' overall wish to be screened | The study compared the two groups' overall wish to be screened as recorded by questionnaire | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Impact of different summary points on subject's desire to be screened | The impact of each of the 6 summary points in the NHS information leaflet on the subject's desire to be screened depending on whether or not they were enhanced by numerical and pictorial information, the summary point that most influenced their decision on whether to be screened; and the views of the intervention group on the numerical and pictorial information provided | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal cancer, consent, screening
Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry

Study Overview
=================
Brief Summary
-----------------
The FIRST project is a national fertility preservation registry for young women facing cancer treatments. The investigators will examine how different cancers and treatments affect the reproductive health of young survivors. This prospective cohort study seeks to recruit young women close to time of cancer diagnosis and treatment. Participants will answer a yearly questionnaire on their current health. A subset of participants will provide dried blood spots to measure reproductive hormones. The primary goal of the study is to determine the risk of infertility and time to pregnancy in young female cancer survivors.

Official Title
-----------------
Fertility Information Research Study

Conditions
-----------------
Cancer, Infertilty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with cancer or exposure to cancer treatment English speaking Ability to consent to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Young female cancer survivors<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of infertility | Participants will be assessed for infertility on average each year from age 18 to 51, the age of natural menopause. | Annually up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to pregnancy |  | Annually up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, fertility preservation, infertility, pregnancy
Acute Effects of Squat Protocols in Muscular Power, Postural Sway and Tendinous Thickness.

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to know the acute effects of a squat protocol in: 1- lower limb muscle power analyzed by countermovement jump on force platform and upper limb through a bench press with encoder test; 2 - the unipodal postural equilibrium by force platform; 3 - the patellar tendinous thickness measured by ultrasound.

Official Title
-----------------
Acute Effects of Squat Protocols in Muscular Power, Postural Sway and Tendinous Thickness.

Conditions
-----------------
Acute Squat Training Effects

Intervention / Treatment
-----------------
* Other: Squat protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males, with at least a year of experience in heavylift exercises, age between 20 and 35 years. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 10x10 squat protocol<br> | Other: Squat protocol<br>* 60% of 1RM weight for 100 squat reps<br>|
| Experimental: As Fast As Possible 100 squat protocol<br> | Other: Squat protocol<br>* 60% of 1RM weight for 100 squat reps<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle power | Muscle power of lower limbs measured by countermovement jump on force platform | 30 minutes | 
| Patellar thickness | Tendon thickness of the patellar tendon measured by ultrasound | 60 minutes | 
| Monopodal Postural Sway | Monopodal postural balance with open eyes in force platform | 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscular fatigue | Muscle fatigue measured in each resting period by means of a countermoving jump to assess the loss of power. | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Squat, Acute effect, Tendon thickness, Counter movement jump test, Postural sway, Muscular power
Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients

Study Overview
=================
Brief Summary
-----------------
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Hyperandrogenism is the central feature of PCOS. Studies on isolated ovarian theca-interstitial cells indicate that resveratrol, a natural polyphenol, reduces androgen production. This study is designed to evaluate the endocrine and metabolic effects of simvastatin and resveratrol on PCOS. Methods: A randomized (1:1) double-blind, placebo-controlled trial will evaluate the effects of administering 20 mg of simvastatin daily and 500 mg of resveratrol daily, or administering 20 mg simvastatin and the placebo to women with PCOS at an academic hospital. PCOS is defined according to the Rotterdam criteria. Evaluations are performed at baseline and repeated after 3 and 6 months of treatment. The main outcome is a change of the serum total testosterone and the fasting insulin level.

Official Title
-----------------
Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome.

Conditions
-----------------
PCOS, Insulin Resistance

Intervention / Treatment
-----------------
* Drug: Simvastatin and micronized trans-resveratrol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PCOs insulin resistance normal prolactin, TSH, 17 OH progesterone No evidence of androgen producing malignancy, Cushing's syndrome or acromegaly Exclusion Criteria: use of oral contraceptives and/or other steroid hormones 3 months prior to the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Simvastatin + resveratrol<br>simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily | Drug: Simvastatin and micronized trans-resveratrol<br> <br> |
| Placebo Comparator: simvastatin+ placebo<br>simvastatin 20 mg daily Placebo | Drug: Simvastatin and micronized trans-resveratrol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| testosterone serum concentration |  | 2 years |
Treatment for the Mental Health Impact of Killing in War

Study Overview
=================
Brief Summary
-----------------
The goal of this project is to test the feasibility, acceptability, and efficacy of a treatment module addressing the mental health and functional impact of killing in the war zone. The investigators will enroll between 12-20 Veterans who have killed in war and have been diagnosed with post-traumatic stress disorder (PTSD) for a pilot study assessing the efficacy of the six-session treatment. Veterans will be randomized either to the treatment or to the waitlist control group.

Official Title
-----------------
Treatment for the Mental Health Impact of Killing in War: Augmentation of Existing Evidence-Based Mental Health Interventions

Conditions
-----------------
Posttraumatic Stress Disorder (PTSD)

Intervention / Treatment
-----------------
* Behavioral: Impact of Killing CBT Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PTSD Veteran will need to endorse having taken another life in a war zone context Have received some prior evidence-based treatment for PTSD Exclusion Criteria: Meet current or lifetime criteria for a psychotic disorder Participants in current PTSD treatment will not be excluded;however,if receiving medications they will need to be stabilized on current medications for at least one month. If receiving Prolonged Exposure Therapy or Cognitive Behavioral Therapy, individuals will need to wait two weeks after they have completed the treatment to enroll in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in psychological symptoms as measured by the Symptom Checklist-90 (SCL-90-R) | A brief multidimensional self-report inventory that screens for nine symptoms of psychopathology and provides three global distress indicators. | Measured at baseline and study completion (week 7) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in killing-related maladaptive cognitions as measured by the Killing Cognitions Scale (KCS) | Assesses killing-related maladaptive cognitions | Measured at baseline and study completion (week 7) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PTSD, Veterans, Killing, Military
Capnographic Monitoring of Propofol-sedation During Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The present study is a randomized, prospective, single-blinded study. Patients presenting for colonoscopy under sedation will be included according to the statistical sample size calculation. Patients will be randomized to either group 1- capnographic monitoring or group 2- oxygenic monitoring during Propofol-based sedation for colonoscopy. Episodes of Hypoxia are documented and compared in both groups.

Official Title
-----------------
Capnographic Monitoring of Propofol-sedation During Colonoscopy

Conditions
-----------------
Hypoxia

Intervention / Treatment
-----------------
* Device: Microcap (Oridion, Needham, MA, USA)
* Device: Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for colonoscopy Patient wishing sedation during colonoscopy ≥ 18 years of age Signed informed consent form Exclusion Criteria: Diseases which preclude study accomplishment or put the patient at any risk (e.g. psychiatric diseases) Non-contractually capable persons Pregnancy Lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Capnography<br>Capnographic respiration monitoring | Device: Microcap (Oridion, Needham, MA, USA)<br> <br> |
| Active Comparator: Pulse-Oxymetry<br>pulse-oxymetric respiration monitoring | Device: Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoxia (SO2 <90%) | Study objective is to evaluate if a reduction of hypoxic events (SO2 <90% for ≥ 15 sec) can be obtained with capnographic monitoring as compared to standard monitoring of respiration with pulse-oxymetry in patients receiving colonoscopy under Propofol-based sedation |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severe Hypoxia (SO2 <85%) | Evaluate events of severe hypoxia (SO2 < 85%) in group 1 (capnographic monitoring) as compared to group 2 (oxymetric monitoring) |  | 
| Time to hypoxia | Evaluate the time difference between abnormal ventilation shown on capnography machine and hypoxemia. |  | 
| Hypoxia in relation to sedation | Compare events of hypoxemia and severe hypoxemia during sedation with propofol only as compared to propofol/ketamin combination sedation. |  | 
| Vegetative Symptoms | Evaluate vegetative events (hypotension, hypertension, bradycardia, tachycardia, tachypnea, bradypnea) in both groups during the two sedation forms |  |
Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve

Study Overview
=================
Brief Summary
-----------------
In an era of delayed fertility plans, there is an increasing need for a reliable method to predict ovarian reserve and responsiveness. The current tests include serum FSH, Inhibin B, Mullerian inhibiting factor (MIF) and ultrasonographic measures such as ovarian volume and number of antral follicles are non-specific and with questionable reliability. The biochemical tests represent the function of production of androgens, as a predictor of ovarian reserve, has not been tested yet. Working hypothesis and aims: testing the prognostic capability of hCG stimulating test of theca cells for estimating the ovarian reserve, and by that to calculate better the chance for IVF cycle success

Detailed Description
-----------------
20 women >40 years old and 20 women <35 years old, attended to our IVF unit were included in the study. Another 20 other young women (<35 years) with poor response in previous IVF cycles will be participate. All participants received a single hCG 10000 IU injection on cycle day 2-4. Hormone levels of LH, FSH, E2, P, Testosterone, Androstendione and 17-OHP were taken prior to the injection and on days 1, 3 and 7 afterwards. hCG induced hormone levels will be compared with IVF results

Official Title
-----------------
hCG Stimulating Test of the Thecal Cells to Evaluate the Ovarian Reserve

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Drug: s.c. human chorionic gonadotropin (Pregnyl)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All women on IVF cycle Exclusion Criteria: Any allergy to injection of human chorionic gonadotropin before

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| androgens levels after stimulation in relation to the ovarian reserve |  | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IVF, ovarian reserve, androgens, thecal cells, Fertility Agents, Female